Pyxis Oncology (PYXS) Depreciation & Amortization (CF) (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Depreciation & Amortization (CF) of $2.9 million for Q4 2025, up 426.73% year-over-year from $550000.0 in Q4 2024, and up 449.72% quarter-over-quarter from $527000.0 in Q3 2025.
Pyxis Oncology (PYXS) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $2.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 426.73% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $4.5 million (up 51.27% YoY), while the FY2025 annual figure was $4.5 million, up 51.27% from the prior year.
- Depreciation & Amortization (CF) advanced to $2.9 million in Q4 2025 per PYXS's latest filing, from $527000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.9 million in Q4 2025 and bottomed at $113000.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $538800.0 across 5 years, with a median of $523500.0 in 2023.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 487.37% — and 2025, when it tumbled 50.54%.
- Pyxis Oncology's Depreciation & Amortization (CF) stood at $158000.0 in 2021, then increased by 21.52% to $192000.0 in 2022, then surged by 259.38% to $690000.0 in 2023, then slipped by 20.29% to $550000.0 in 2024, then jumped by 426.73% to $2.9 million in 2025.
- Business Quant data shows PYXS's Depreciation & Amortization (CF) at $2.9 million in Q4 2025, $527000.0 in Q3 2025, and $535000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | 527,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 535,000.00 |
| Jun 30, 2025 | 535,000.00 |
| Mar 31, 2025 | 552,000.00 |
| Mar 31, 2025 | 552,000.00 |
| Dec 31, 2024 | 550,000.00 |
| Dec 31, 2024 | 550,000.00 |
| Sep 30, 2024 | 731,000.00 |
| Sep 30, 2024 | 731,000.00 |
| Jun 30, 2024 | 585,000.00 |
| Jun 30, 2024 | 585,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 690,000.00 |
| Dec 31, 2023 | 690,000.00 |
| Sep 30, 2023 | 523,000.00 |
| Sep 30, 2023 | 523,000.00 |